AlphAIalphai — Financial news for AI agents
simplywall.stAUG 222 min read$VRSK

Is Verisk Analytics (VRSK) Undervalued As Q2 Earnings Beat Expectations?

Verisk Analytics (VRSK) reported Q2 2026 adjusted EPS and revenue exceeding analyst forecasts, driven by subscription revenue. Shares are up 9.58% over 90 days but down 15.17% year-to-date. The company trades at a discount to analyst targets, with differing valuations: Esteban estimates a fair value of $76.85, while a DCF model suggests $231.91. Risks include slower revenue growth and weaker client retention.

Original reporting
simplywall.st
Published Aug 22, 2026, 8:22 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 23, 2026, 1:25 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$VRSK
Bullish
medium confidence
Mentioned
$VRSK
Relevance
6/10
alphai data visualization · based on simplywall.st
Decision brief

The 30-second read

$VRSKBullishMed
01

Why it matters

The divergent valuations highlight uncertainty; traders should watch upcoming guidance for direction.

02

Market read

Earnings beat may spark short‑term buying, but valuation debate tempers long‑term conviction.

03

What to watch

Potential slowdown in subscription growth or client retention could reverse the rally.

Relevance 6/10Novelty 6/10Timing: pre‑market

Background

Simply Wall St provides a valuation comparison, noting divergent fair‑value estimates ranging from $76.85 to $231.91.

Company-level read

Ticker impact

$VRSKBullishMedium confidence
Context

Verisk Analytics reported Q2 2026 adjusted EPS and revenue that beat analyst forecasts, prompting a 9.58% share price gain over 90 days.

Expected impact

Potential upside of 5‑8% over the next week if momentum holds.

Evidence & confidence

The beat is a fresh earnings disclosure for a large‑cap data provider; no detailed guidance was given, so upside is limited to momentum.

Market effects

Sector

Positive for the insurance‑data and subscription‑revenue sector, may lift peers with similar business models.

Regional

U.S. market focus, limited global spillover.

Global

Modest, confined to U.S. insurance‑tech space.

Counterpoint

What could challenge this read

The beat may be modest and the stock could be overbought after a sharp rebound; valuation concerns remain.

Key entities

  • company
    Verisk Analytics

    U.S. data and analytics provider for the property & casualty insurance industry.

Read at source← All news

Related articles

AUG 19
$VRSKMedAI 8/10

Verisk Analytics v. AccuLynx: Sorry, You Actually DO Have To Comply With That Second Request

The Delaware Court of Chancery ordered Verisk Analytics to continue pursuing FTC clearance for its $2.35 billion acquisition of AccuLynx, despite Verisk's attempt to terminate the deal. The court ruled that Verisk's termination was invalid due to its willful conduct in ending negotiations with a competitor, ServiceTitan. Verisk must now comply with a costly Second Request process, which typically takes many months to complete. The court's decision is notable as it is the first to compel a buyer

marketscreener.com2 min
AUG 10
$VRSKMed

Verisk Told It Can't Abandon $2.35B AccuLynx Deal

Delaware Chancery Court ruled that Verisk Analytics Inc. improperly exited its $2.35 billion acquisition of AccuLynx, according to the court. The decision requires Verisk to proceed with the deal, affecting the timing and terms of the insurance data and software transaction for investors.

law360.com2 min
AUG 10
$VRSKMed

Why is Verisk Analytics stock sliding today?

Verisk Analytics shares fell 5.6% after the Delaware Chancery Court ruled Verisk must proceed with its $2.35 billion AccuLynx acquisition. The court said Verisk’s conduct invalidated its Dec 2025 deal termination and awarded AccuLynx damages plus interest. Verisk said it strongly disagrees and is evaluating next steps, including a possible appeal, while FTC antitrust review remains unresolved.

investing.com4 min
AUG 10
$VRSKMedAI 8/10

Verisk stock falls after court rejects $2.35B merger termination

Verisk Analytics (NASDAQ:VRSK) shares fell about 5.5% after a Delaware Chancery Court rejected Verisk’s bid to terminate its $2.35B acquisition of AccuLynx. The court said Verisk’s termination was invalid and AccuLynx is owed damages for direct costs plus interest. Verisk said it strongly disagrees and is evaluating options, including an appeal.

investing.com4 min
AUG 10
$VRSKMedAI 8/10

Verisk Slides as Court Revives AccuLynx Deal Fight

Verisk Analytics (VRSK) fell about 5% as a Delaware Court of Chancery ruling revived its dispute over the terminated AccuLynx acquisition. Verisk agreed to buy AccuLynx in July 2025 and terminated in Dec. 2025. The court required Verisk to pursue regulatory approval efforts for the $2.35 billion deal. Verisk reported Q2 2026 revenue of $806 million.

quiverquant.com6 min